This retrospective electronic health record study followed 9,189 adults with obesity but without diabetes. All started subcutaneous semaglutide or tirzepatide and were followed for 12 months. Coverage under 32 days occurred in 36.7%, and 82.7% of these had no further antiobesity prescriptions that year. Of those covered for 32-179 days (27.0%) or 180-335 days (17.7%), 72.3% and 89.5% respectively had none thereafter. Only 18.6% had coverage of 336 days or more, and reinitiation or switching to another agent was rare. The data come from a single academic medical centre and a retrospective design.
Why it is interesting: Use of GLP-1-based drugs for obesity is rising, yet fewer than one in five adults here had near year-long coverage. Restarting or switching was rare, so most who stopped were prescribed no other antiobesity medication that year.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Behavioural science
-
Diet, exercise and sleep
What people eat and how much they move: what the measured evidence says each does to mortality, and what has been shown to change either.
2 this week -
Smoking and vaping
How far smoking has fallen and how many deaths it still causes, what vaping is doing to the people who take it up, and what generational bans will show.
4 this week -
Alcohol and drug use
What is happening to deaths from alcohol, drugs and suicide, whether they move together, and how much of it is behaviour and how much circumstance.
5 this week -
Social connection
Isolation, loneliness and mortality: what the evidence shows, how far the relationship is causal, and what interventions have shown.
None this week Earlier → -
Infection and pandemics
Infection and pandemics: the risks, and how well prepared we are
8 this week -
Adherence and persistence
Whether a treatment is actually taken, for how long, and what changes either.
3 this week
